Voyager Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
VYGR$1.83-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) Income
(amounts in thousands, except share and per share data)
| | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended · · Nine Months Ended · | |||||||||||||
| · · September 30, · September 30, | |||||||||||||
| · 2024 · 2023 · 2024 · 2023 | |||||||||||||
| Collaboration revenue | | $24,629 | $4,614 | | $73,723 | $159,947 | | ||||||
| Operating expenses: | | | | | | | | | | | | | |
| Research and development | | 30,241 | | 25,863 | | 91,785 | | 66,416 | | ||||
| General and administrative | | 8,168 | | 8,258 | | 26,926 | | 25,580 | | ||||
| Total operating expenses | | 38,409 | | | 34,121 | | 118,711 | | | 91,996 | | ||
| Operating (loss) income | | | (13,780) | | | (29,507) | | | (44,988) | | | 67,951 | |
| Interest income | | 4,579 | | 3,429 | | 14,334 | | 8,567 | | ||||
| Other income | | 200 | | — | | 220 | | 3 | | ||||
| Total other income, net | | 4,779 | | 3,429 | | 14,554 | | 8,570 | | ||||
| (Loss) income before income taxes | | | (9,001) | | | (26,078) | | | (30,434) | | | 76,521 | |
| Income tax provision (benefit) | | | 43 | | | (177) | | | 81 | | | 586 | |
| Net (loss) income | | $(9,044) | | $(25,901) | | $(30,515) | | $75,935 | | ||||
| Other comprehensive (loss) income: | | | | | | | | | | | | | |
| Net unrealized gain (loss) on available-for-sale securities | | 489 | | (115) | | 15 | | (29) | | ||||
| Total other comprehensive income (loss) | | 489 | | (115) | | 15 | | (29) | | ||||
| Comprehensive (loss) income | | $(8,555) | | $(26,016) | | $(30,500) | | $75,906 | | ||||
| | | | | | | | | | | | | | |
| Net (loss) income per share, basic | | $(0.16) | | $(0.59) | | $(0.53) | | $1.85 | | ||||
| Net (loss) income per share, diluted | | $(0.16) | | $(0.59) | | $(0.53) | | $1.78 | | ||||
| | | | | | | | | | | | | | |
| Weighted-average common shares outstanding, basic | | | 57,851,110 | | | 43,864,838 | | | 57,564,413 | | | 40,962,116 | |
| Weighted-average common shares outstanding, diluted | | | 57,851,110 | | | 43,864,838 | | | 57,564,413 | | | 42,610,724 | |
| | | | | | | | | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.